Search Results for:
-
Flush Thrush: Bluebird's IPO At 'Beak' Value, Gets $101M
Agios Pharmaceuticals Inc., also of Cambridge, Mass., filed earlier this month for an IPO to raise up to $86 million to fund development of its pipeline in cancer and inborn errors of metabolism, a subset of orphan genetic metabolic diseases...Intercept Pharmaceuticals Inc., of New York, priced an underwritten public offering of about 1.7 million shares of its common stock at a price of $33.01 per share, for gross proceeds of about $57 million -
A&G Pharmaceutical Inc.
-
Aarden Pharmaceuticals Inc.
-
Acadia Pharmaceuticals Inc.
-
Access Pharmaceuticals Inc.
-
AcelRx Pharmaceuticals Inc.
-
Acetylon Pharmaceuticals Inc.
-
Achillion Pharmaceuticals Inc.
-
Adamas Pharmaceuticals Inc.
-
Aegerion Pharmaceuticals Inc.
-
Aeolus Pharmaceuticals Inc.
-
Aerie Pharmaceuticals Inc.
-
Afferent Pharmaceuticals Inc.
-
Affinium Pharmaceuticals Inc.
-
Agios Pharmaceuticals Inc.
-
Aida Pharmaceuticals Inc.
-
Alexion Pharmaceuticals Inc.
-
Alexza Pharmaceuticals Inc.
-
Allele Biotechnology and Pharmaceuticals Inc.
-
Alnara Pharmaceuticals Inc.
Category
Current Filters
- xPharmaceuticals Inc
Related Keywords
Categories
- x BioWorld Today (14128)
- x BioWorld Insight (3060)
- x BioWorld International (717)
- x Bio Perspectives (325)
- x State of the Industry Report (316)
- x Bioscan (211)
- x BioWorld Genomics Review (148)
- x BioWorld Phase III Report (139)
- x Executive Compensation Report (105)
- x BioWorld Snapshots (86)
- x Top 25 Drug Report (52)
- x Biotech Innovations (32)
- x Market-Leading Biotech Drugs (8)
- x RNAi Report (5)